Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. experienced a strong opening with significant market activity, outperforming the S&P 500 for the day. However, the company has struggled recently, with a notable decline over the past month. Financial metrics reveal concerns about debt servicing and operational efficiency amidst its small-cap status.

Collegium Pharmaceutical, Inc. faced a notable stock decline today, contrasting with the S&P 500's minimal change. Despite recent challenges, the company has shown strong long-term growth in net sales and operating profit. However, its financial metrics indicate a difficult environment, with the stock trading at a discount relative to peers.

Collegium Pharmaceutical, Inc. has reached a new 52-week low, reflecting a notable decline in its stock performance over the past year. Despite this, the company maintains a solid market capitalization and demonstrates long-term growth in net sales and operating profit, although recent profits have decreased.

Collegium Pharmaceutical, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators suggest a bearish outlook, despite a solid one-year performance. The stock's longer-term metrics show challenges compared to the S&P 500, warranting close monitoring.

Collegium Pharmaceutical, Inc. opened with a significant loss, reflecting a broader trend of decline over the past day and month, contrasting with the S&P 500's performance. The company has a market cap of approximately USD 1.461 billion, a P/E ratio of 21.00, and a high debt-to-equity ratio of 2.28.

Collegium Pharmaceutical, Inc. achieved a new 52-week high, reflecting strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 1,222 million, the company shows effective management through a return on equity of 23.11%, despite a higher reliance on debt financing and no dividend offerings.

Collegium Pharmaceutical, Inc. has adjusted its valuation, showcasing a favorable P/E ratio of 15 and strong profitability metrics, including a ROCE of 16.93% and ROE of 28.03%. The company has outperformed the S&P 500 in stock returns over both year-to-date and annual periods, highlighting its competitive market position.

Collegium Pharmaceutical, Inc. has seen notable stock activity, with a significant increase today and strong weekly and monthly gains. Despite its annual performance exceeding that of the S&P 500, the company faces challenges, including a low EBIT to Interest ratio and a decline in pre-tax profit in its latest quarterly results.

Collegium Pharmaceutical, Inc. achieved a new 52-week high of USD 41.81 on November 6, 2025, reflecting strong performance over the past year. The company, with a market cap of USD 1,222 million, has shown a one-year growth of 22.07%, outperforming the S&P 500. Key metrics indicate solid financial health despite a high debt-to-equity ratio.

Collegium Pharmaceutical, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $36.10. The company has experienced significant volatility over the past year, with a high of $39.95 and a low of $23.23, while showing mixed technical indicators and notable performance relative to the S&P 500.

Collegium Pharmaceutical, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 15 and a price-to-book value of 4.25. The company exhibits strong operational efficiency with a return on equity of 28.03% and a year-to-date stock performance of 25.65%, surpassing the S&P 500.

Collegium Pharmaceutical, Inc. has recently adjusted its valuation, with a P/E ratio of 15 and a Price to Book Value of 4.25. The company shows strong operational performance, reflected in its ROCE of 16.93% and ROE of 28.03%, and has outperformed the S&P 500 over three years.

Collegium Pharmaceutical, Inc. has recently seen a stock price adjustment, currently at $34.41. Over the past year, it reached a high of $42.29 and a low of $23.23. The company has outperformed the S&P 500 year-to-date but faced a decline in the past month, reflecting market volatility.

Collegium Pharmaceutical, Inc. has recently seen a stock price adjustment, currently at $35.75. The company has experienced significant volatility over the past year, with a 52-week high of $42.29 and a low of $23.23. Its performance has varied, showing strong returns over three years compared to the S&P 500.